Last reviewed · How we verify
A Randomized Phase III Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer (RASTEN)
The endpoint is to investigate if the addition of low molecular heparin - enoxaparin, will result in a significant increase of overall survival in patients with small cell lung cancer, receiving standard chemotherapy.
Details
| Lead sponsor | Lund University Hospital |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 390 |
| Start date | 2008-06 |
| Completion | 2017-05 |
Conditions
- Small Cell Lung Cancer
Interventions
- cisplatinum or carboplatin and e.g.etoposide.
- cisplatinum or carboplatin and e.g.etoposide+enoxaparin
Primary outcomes
- Significant increase of overall survival — At follow up 1 year after treatment
Countries
Sweden